Abstract:Tumor cells are usually considered defective in mitochondrial respiration, but human non-small cell lung cancer (NSCLC) tumor tissues are shown to have enhanced glucose oxidation relative to adjacent benign lung. Here, we reported that oncoprotein cancerous inhibitor of protein phosphatase 2A (CIP2A) inhibited glycolysis and promoted oxidative metabolism in NSCLC cells. CIP2A bound to pyruvate kinase M2 (PKM2) and induced the formation of PKM2 tetramer, with serine 287 as a novel phosphorylation site essential for PKM2 dimer-tetramer switching. CIP2A redirected PKM2 to mitochondrion, leading to upregulation of Bcl2 via phosphorylating Bcl2 at threonine 69. Clinically, CIP2A level in tumor tissues was positively correlated with the level of phosphorylated PKM2 S287. CIP2A-targeting compounds synergized with glycolysis inhibitor in suppressing cell proliferation in vitro and in vivo. These results indicated that CIP2A facilitates oxidative phosphorylation by promoting tetrameric PKM2 formation, and targeting CIP2A and glycolysis exhibits therapeutic potentials in NSCLC.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to explore how CIP2A (Cancerous Inhibitor of Protein Phosphatase 2A) regulates metabolic reprogramming in non - small - cell lung cancer (NSCLC), especially its effect on the oligomerization of pyruvate kinase M2 (PKM2) and its mechanism. Specifically, the study aims to reveal that CIP2A promotes oxidative phosphorylation by inducing the formation of PKM2 tetramers and explain the impact of this regulation on the metabolism and proliferation of NSCLC cells. ### Summary of the core issues in the paper: 1. **The role of CIP2A**: Does CIP2A affect the metabolic pathways in NSCLC cells? If so, how? 2. **Regulation of PKM2**: Can CIP2A regulate the oligomerization state of PKM2? If yes, what is the specific mechanism? 3. **Metabolic reprogramming**: Can CIP2A change the cell's metabolic pattern from aerobic glycolysis to oxidative phosphorylation by regulating PKM2 oligomerization? 4. **Clinical significance**: Do these findings have potential therapeutic application value? ### Research background: - The traditional view is that tumor cells rely on aerobic glycolysis (Warburg effect), but recent studies have shown that some types of tumor cells, such as NSCLC, may retain or even enhance mitochondrial respiratory function. - CIP2A is a multifunctional oncogenic protein. It is known to interact with multiple proteins and participate in multiple signaling pathways, but its specific role in metabolic regulation is not clear. - PKM2 is a key enzyme in the glycolytic pathway, and its form (monomer, dimer or tetramer) determines its catalytic activity and subcellular localization. ### Main findings: 1. **Interaction between CIP2A and PKM2**: CIP2A can directly bind to PKM2 and regulate its activity by stabilizing the formation of PKM2 tetramers. 2. **Phosphorylation at site S287**: CIP2A promotes the conversion of PKM2 from dimer to tetramer by phosphorylating the S287 site of PKM2. 3. **Metabolic regulation**: CIP2A changes the metabolism from aerobic glycolysis to oxidative phosphorylation by regulating the oligomerization state of PKM2, thus supporting the growth and survival of tumor cells. 4. **Clinical relevance**: The level of CIP2A is positively correlated with the level of pS287 - PKM2 in NSCLC tissues, suggesting its potential diagnostic and therapeutic value in the clinic. Through these studies, the authors have revealed a new mechanism of CIP2A in the metabolic regulation of NSCLC and provided a theoretical basis for the development of combined therapies targeting CIP2A and glycolysis.

CIP2A induces PKM2 tetramer formation and oxidative phosphorylation in non-small cell lung cancer

Targeting MYC-enhanced Glycolysis for the Treatment of Small Cell Lung Cancer

Abstract 7062: CIP2A enhances mitochondrial respiratory electron transport chain complexes and induces lung cancer in vivo

Abstract 7062: CIP2A enhances mitochondrial respiratory electron transport chain complexes and induces lung cancer <i>in vivo</i>

Simultaneous suppression of PKM2 and PHGDH elicits synergistic anti-cancer effect in NSCLC

Interplay Of Mkp-1 And Nrf2 Drives Tumor Growth And Drug Resistance In Non-Small Cell Lung Cancer

Protein kinase C-iota-mediated glycolysis promotes non-small-cell lung cancer progression.

PPIP5K2 Facilitates Proliferation and Metastasis of Non-Small Lung Cancer (NSCLC) through AKT Signaling Pathway

Targeting Pyruvate Kinase M2 Contributes to Radiosensitivity of Non-Small Cell Lung Cancer Cells in Vitro and in Vivo.

PKM2 Dephosphorylation by Cdc25A Promotes the Warburg Effect and Tumorigenesis

Phosphoenolpyruvate carboxykinase 2-mediated metabolism promotes lung tumorigenesis by inhibiting mitochondrial-associated apoptotic cell death

Enhanced Expression of PKM2 Associates with the Biological Properties of Cancer Stem Cells from A549 Human Lung Cancer Cells

Inhibition of CIP2A Attenuates Tumor Progression by Inducing Cell Cycle Arrest and Promoting Cellular Senescence in Hepatocellular Carcinoma

Targeting Mitochondrial IDH2 Enhances Antitumor Activity of Cisplatin in Lung Cancer via ROS-Mediated Mechanism

Endogenous PP2A inhibitor CIP2A degradation by chaperone-mediated autophagy contributes to the antitumor effect of mitochondrial complex I inhibition

Mitochondrial PKM2 Regulates Oxidative Stress-Induced Apoptosis by Stabilizing Bcl2

Inhibition of Protein Kinase CK2 Sensitizes Non-Small Cell Lung Cancer Cells to Cisplatin Via Upregulation of PML

Pim-2 Modulates Aerobic Glycolysis and Energy Production During the Development of Colorectal Tumors.

ULK1-dependent phosphorylation of PKM2 antagonizes O-GlcNAcylation and regulates the Warburg effect in breast cancer

PKM2 Coordinates Glycolysis with Mitochondrial Fusion and Oxidative Phosphorylation

Novel Specific Pyruvate Kinase M2 Inhibitor, Compound 3h, Induces Apoptosis and Autophagy through Suppressing Akt/mTOR Signaling Pathway in LNCaP Cells